Tyrosine kinase inhibitorPhase 3 trialInvestigational
Cediranib
How it works
Blocks the action of vascular endothelial growth factor receptors (VEGFR), which helps cancer cells grow new blood vessels.
Cancer types
Ovarian Cancer— All patients
Efficacy
Cediranib has shown promise in improving response rates and progression-free survival in ovarian cancer patients, particularly when combined with chemotherapy.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Cediranib and Olaparib Combination Therapy for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Testing New Treatments for Women with Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Testing a Combination of Two Drugs for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Cediranib and Olaparib in Ovarian and Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing Cediranib and Olaparib in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Combination of Cediranib and Selumetinib in Advanced Cancer Patients | Melanoma | phase-1 | — | Source → |
| Olaparib and Cediranib Combination in Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | The combination significantly prolonged progression-free survival (PFS) (overall HR = 0.78; 95% CI: 0.68-0.89; < 0.001). | Source → |
| Combining Paclitaxel and Cediranib for Ovarian Cancer Patients at Risk of Bowel Obstruction | Ovarian Cancer | phase-2 | The objective response in patients who received paclitaxel and cediranib was 65.0%. | Source → |
| Combination Cediranib and Olaparib Shows Activity in Ovarian Cancer | Ovarian Cancer | phase-2 | In platinum-sensitive ovarian cancer, the overall response rate was 77.1% and median progression-free survival was 16.4 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.